Isotachophoresis of blood-derived samples
View Patent ↗Methods are provided for forming a complex comprising an analyte (or an analyte analog) from a blood-derived sample and labeling substances, and separating the complex from excess labeling substances and coexisting substances from the blood-derived sample, in a rapid, simple, convenient, and highly precise isotachophoresis (ITP) process by adding 2-(N-morpholino)ethane sulfonate (MES) salt and/or glutamate salt to the ITP sample. Methods are also provided for measuring the analyte in blood-derived samples with high precision and high sensitivity, based on the amount of the complex separated or the amount of uncomplexed labeling substance-containing molecules.
1. A method for separating a complex, the method comprising:
(1) introducing in a capillary, between a leading buffer zone and a trailing buffer zone, wherein neither the leading buffer nor the trailing buffer comprises an ion selected from a 2-(N-morpholino)ethane sulfonate ion and a glutamate ion: (a) a blood-derived sample suspected of containing an analyte, (b) a labeled analyte analog, and (c) one or more mobility-changing complex forming substances (CFS);
(2) contacting the analyte, the labeled analyte analog, and the one or more mobility-changing CFSs, wherein a first complex comprising the labeled analyte analog and at least one of the one or more mobility-changing CFSs and a second complex comprising the analyte and at least one of the one or more mobility-changing CFSs are formed; and
(3) separating the first complex from the labeled analyte analog not part of said first complex and coexisting substances in the blood-derived sample by performing isotachophoresis in the presence of a 2-(N-morpholino)ethane sulfonate ion and/or a glutamate ion between the leading buffer zone and the trailing buffer zone.
2. The method of claim 1 , wherein the one or more anionic mobility-changing CFSs comprise a double-stranded DNA polynucleotide.
3. The method of claim 1 , wherein the leading buffer comprises chloride as a leading ion.
4. The method of claim 1 , wherein the trailing buffer comprises a trailing ion selected from HEPES, TAPS, MOPS, glycin, and threonine.
5. The method of claim 1 , further comprising after performing isotachophoresis:
(4) subjecting the first complex to capillary zone electrophoresis or capillary gel electrophoresis in the presence of 2-(N-morpholino)ethane sulfonate ion and/or glutamate ion.
6. The method of claim 5 , wherein capillary zone electrophoresis or capillary gel electrophoresis is carried out in the presence of a negatively-charged polymer.
7. A method for separating a complex, the method comprising:
(1) arranging in a capillary, between a leading buffer zone and a trailing buffer zone, wherein neither the leading buffer nor the trailing buffer comprises an ion selected from a 2-(N-morpholino)ethane sulfonate ion and a glutamate ion:
(a) three zones comprising (i) a solution of a blood-derived sample suspected of containing an analyte, (ii) a solution of one or more mobility-changing CFSs, and (iii) a solution of a labeled analyte analog, as separate zones; or
(b) two zones comprising (i) a solution of a blood-derived sample suspected of containing an analyte and (ii) a solution of a labeled analyte analog and one or more mobility-changing CFSs, as separate zones; or
(c) two zones comprising (i) a solution of a labeled analyte analog and (ii) a solution of a blood-derived sample suspected of containing an analyte and one or more mobility-changing CFSs, as separate zones; or
(d) two zones comprising (i) a solution of a blood-derived sample suspected of containing an analyte and a labeled analyte analog and (ii) a solution of one or more mobility-changing CFSs, as separate zones;
(2) contacting the blood-derived sample suspected of containing an analyte, the one or more mobility-changing CFSs, and the labeled analyte analog, wherein a first complex comprising the labeled analyte analog and at least one of the one or more mobility-changing CFSs, and a second complex comprising the analyte and at least one of the one or more mobility-changing CFSs are formed;
(3) separating the first complex from the labeled analyte analog not part of said first complex and coexisting substances in the blood-derived sample by performing isotachophoresis in the presence of a 2-(N-morpholino)ethane sulfonate ion and/or a glutamate ion between the leading buffer zone and the trailing buffer zone; and
(4) separating the first complex and coexisting substances in the blood-derived sample by performing capillary zone electrophoresis or capillary gel electrophoresis.
8. The method of claim 7 , wherein capillary zone electrophoresis or capillary gel electrophoresis is carried out in the presence of a negatively-charged polymer.
9. The method of claim 7 , wherein at the least the solution comprising the blood-derived sample further comprises 2-(N-morpholino)ethane sulfonate ion and/or glutamate ion.
10. The method of claim 7 , wherein the method further comprises quantifying the amount of analyte by detecting the labeled analyte analog present in the first complex and/or the labeled analyte analog not part of said first complex.
11. A method for separating a complex, the method comprising:
(1) introducing in a capillary, between a leading buffer zone and a trailing buffer zone, wherein neither the leading buffer nor the trailing buffer comprises an ion selected from a 2-(N-morpholino)ethane sulfonate ion and a glutamate ion: (a) a blood-derived sample suspected of containing an analyte, (b) a mobility-changing analyte analog, and (c) one or more labeled complex forming substances (CFS);
(2) contacting the analyte, the mobility-changing analyte analog, and the one or more labeled CFSs, wherein a first complex comprising the mobility-changing analyte analog and at least one of the one or more labeled CFSs and a second complex comprising the analyte and at least one of the one or more labeled CFSs are formed; and
(3) separating the first complex from the second complex, the labeled CFSs not part of said first complex or said second complex, and coexisting substances in the blood-derived sample by performing isotachophoresis in the presence of a 2-(N-morpholino)ethane sulfonate ion and/or a glutamate ion between the leading buffer zone and the trailing buffer zone.
12. The method of claim 11 , wherein the anionic mobility-changing analyte analog comprises a double-stranded DNA polynucleotide.
13. The method of claim 11 , wherein the leading buffer comprises chloride as a leading ion.
14. The method of claim 11 , wherein the trailing buffer comprises a trailing ion selected from HEPES, TAPS, MOPS, glycin, and threonine.
15. The method of claim 11 , further comprising after performing isotachophoresis:
(4) subjecting the first complex to capillary zone electrophoresis or capillary gel electrophoresis in the presence of 2-(N-morpholino)ethane sulfonate ion and/or glutamate ion.
16. The method of claim 15 , wherein capillary zone electrophoresis or capillary gel electrophoresis is carried out in the presence of a negatively-charged polymer.
17. A method for separating a complex, the method comprising:
(1) arranging in a capillary, between a leading buffer zone and a trailing buffer zone, wherein neither the leading buffer nor the trailing buffer comprises an ion selected from a 2-(N-morpholino)ethane sulfonate ion and a glutamate ion:
(a) two zones comprising (i) a solution of a blood-derived sample suspected of containing an analyte and (ii) a solution of a mobility-changing analyte analog and one or more labeled CFSs, as separate zones; or
(b) two zones comprising (i) a solution of a mobility-changing analyte analog and (ii) a solution of a blood-derived sample suspected of containing an analyte and one or more labeled CFSs, as separate zones;
(2) contacting the blood-derived sample suspected of containing an analyte, the one or more labeled CFSs, and the mobility-changing analyte analog, wherein a first complex comprising the mobility-changing analyte analog and at least one of the one or more labeled CFSs, and a second complex comprising the analyte and at least one of the one or more labeled CFSs are formed;
(3) separating the first complex from the second complex, the labeled CFSs not part of said first complex or said second complex, and coexisting substances in the blood-derived sample by performing isotachophoresis in the presence of a 2-(N-morpholino)ethane sulfonate ion and/or a glutamate ion between the leading buffer zone and the trailing buffer zone; and
(4) separating the first complex and coexisting substances in the blood-derived sample by performing capillary zone electrophoresis or capillary gel electrophoresis.
18. The method of claim 17 , wherein capillary zone electrophoresis or capillary gel electrophoresis is carried out in the presence of a negatively-charged polymer.
19. The method of claim 17 , wherein at the least the solution comprising the blood-derived sample further comprises 2-(N-morpholino)ethane sulfonate ion and/or glutamate ion.
20. The method of claim 17 , wherein the method further comprises quantifying the amount of analyte by detecting the labeled CFS present in the first complex and/or the second complex and/or the labeled CFS not part of said first complex or said second complex.